Axonal Degeneration in AD: The Contribution of Aβ and Tau

Frontiers in Aging Neuroscience
Natalia SalvadoresFelipe A Court

Abstract

Alzheimer's disease (AD) represents the most common age-related neurodegenerative disorder, affecting around 35 million people worldwide. Despite enormous efforts dedicated to AD research over decades, there is still no cure for the disease. Misfolding and accumulation of Aβ and tau proteins in the brain constitute a defining signature of AD neuropathology, and mounting evidence has documented a link between aggregation of these proteins and neuronal dysfunction. In this context, progressive axonal degeneration has been associated with early stages of AD and linked to Aβ and tau accumulation. As the axonal degeneration mechanism has been starting to be unveiled, it constitutes a promising target for neuroprotection in AD. A comprehensive understanding of the mechanism of axonal destruction in neurodegenerative conditions is therefore critical for the development of new therapies aimed to prevent axonal loss before irreversible neuronal death occurs in AD. Here, we review current evidence of the involvement of Aβ and tau pathologies in the activation of signaling cascades that can promote axonal demise.

References

Jun 15, 1992·FEBS Letters·K M BroekemeierD R Pfeiffer
Oct 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·M F LyonV H Perry
Jan 1, 1995·Clinical Anatomy : Official Journal of the American Association of Clinical Anatomists & the British Association of Clinical Anatomists·A AlzheimerF R Murtagh
Jul 1, 1997·Neurobiology of Aging·H Braak, E Braak
Feb 24, 1999·Journal of Neuropathology and Experimental Neurology·R MorschP D Coleman
Oct 12, 2000·Proceedings of the National Academy of Sciences of the United States of America·L ConfortiM P Coleman
Apr 18, 2002·Proceedings of the National Academy of Sciences of the United States of America·Mark RapoportAdriana Ferreira
Jan 1, 1989·The European Journal of Neuroscience·E R LunnS Gordon
Oct 1, 1991·The European Journal of Neuroscience·V H PerryE R Lunn
Oct 3, 2002·Journal of Neurochemistry·Della C DavidMaria Grazia Spillantini
Aug 23, 2003·Journal of Neurology, Neurosurgery, and Psychiatry·R J HarveyM N Rossor
Dec 4, 2003·Neurobiology of Aging·E-M MandelkowE Mandelkow
Apr 7, 2004·The Journal of Cell Biology·Laura Korhonen, Dan Lindholm
Nov 6, 2004·Reviews in the Neurosciences·Tara L Spires, Bradley T Hyman
Dec 14, 2004·Cell Death and Differentiation·H KadowakiH Ichijo
Jan 11, 2005·Neurotoxicity Research·Adele WoodhouseTracey C Dickson
Jan 26, 2005·The Journal of Clinical Investigation·Robert P BrendzaDavid M Holtzman
Feb 26, 2005·Science·Gorazd B StokinLawrence S B Goldstein
Mar 9, 2005·Journal of Neuropathology and Experimental Neurology·Ralph A NixonAna Maria Cuervo
Jul 27, 2005·The Journal of Cell Biology·Jing WangZhigang He
Aug 27, 2005·Neurobiology of Aging·Mee-Sook SongElena I Posse de Chaves
Oct 15, 2005·Nature Reviews. Neuroscience·Michael Coleman
Nov 18, 2005·Neurobiology of Aging·Stephen W ScheffElliott J Mufson
Jun 21, 2006·Proceedings of the National Academy of Sciences of the United States of America·Travis R StoubRaj C Shah

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
chemical interventions
transgenic

Related Concepts

Related Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.